Search
Amphastar Pharmaceuticals Inc
AMPHAdd to Watchlist
23.620USD
-0.200-0.84%
Close 09-18 16:00（ET）
1.00BMarket Cap
13.80P/E TTM
Amphastar Pharmaceuticals Inc (AMPH) Revenue Performance
Updated: Jun 30, 2026Last year, Amphastar Pharmaceuticals Inc generated 229.65M USD for its biggest-performing segment, Other products. The United States made the largest contribution, accounting for 681.42M USD last year. For the latest quarter, Amphastar Pharmaceuticals Inc reported the revenue of 40.41M USD for the period ending 2024-09-30, which came from the top-performing segment, BAQSIMI. United States contributed the highest revenue, at 172.34M USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Other products
BAQSIMI
Primatene Mist
Epinephrine
Glucagon
Lidocaone
Other Revenues
Phytonadione
Enoxaparina
Naloxone
Other finished pharmaceutical products
Primatene® Mist
BAQSIMI NEB
Medroxyprogesterone
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Other products
229.65M(31.90%)
145.03M(19.81%)
--(--)
--(--)
--(--)
--(--)
--(--)
BAQSIMI
185.36M(25.75%)
126.90M(17.34%)
--(--)
--(--)
--(--)
--(--)
--(--)
Primatene Mist
108.67M(15.10%)
102.01M(13.94%)
89.32M(12.41%)
--(--)
--(--)
--(--)
--(--)
Epinephrine
70.64M(9.81%)
94.09M(12.85%)
81.65M(11.35%)
74.20M(15.25%)
57.53M(13.71%)
23.80M(7.18%)
13.88M(4.60%)
Glucagon
69.08M(9.60%)
108.32M(14.80%)
113.68M(15.80%)
55.32M(11.37%)
47.64M(11.35%)
--(--)
--(--)
Lidocaone
56.48M(7.85%)
55.85M(7.63%)
58.16M(8.08%)
52.54M(10.80%)
44.41M(10.59%)
41.11M(12.41%)
46.01M(15.24%)
Other Revenues
--(--)
19.15M(2.62%)
--(--)
--(--)
--(--)
--(--)
--(--)
Phytonadione
--(--)
43.17M(5.90%)
44.94M(6.25%)
49.50M(10.17%)
45.50M(10.84%)
42.65M(12.87%)
45.79M(15.16%)
Enoxaparina
--(--)
21.71M(2.97%)
31.53M(4.38%)
34.95M(7.18%)
35.96M(8.57%)
48.68M(14.69%)
42.70M(14.14%)
Naloxone
--(--)
15.73M(2.15%)
19.00M(2.64%)
26.27M(5.40%)
27.54M(6.56%)
33.42M(10.08%)
34.76M(11.51%)
Other finished pharmaceutical products
--(--)
--(--)
140.82M(19.57%)
109.41M(22.49%)
87.88M(20.94%)
89.99M(27.16%)
72.94M(24.15%)
Primatene® Mist
--(--)
--(--)
89.32M(12.41%)
84.31M(17.33%)
73.11M(17.43%)
51.73M(15.61%)
18.07M(5.98%)
BAQSIMI NEB
--(--)
--(--)
51.16M(7.11%)
--(--)
--(--)
--(--)
--(--)
Medroxyprogesterone
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
27.85M(9.22%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
France
China
United Kingdom
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States
681.42M(94.66%)
707.68M(96.68%)
635.19M(98.57%)
486.83M(97.56%)
419.87M(95.91%)
333.09M(95.21%)
304.90M(94.58%)
279.12M(94.72%)
France
35.28M(4.90%)
19.95M(2.73%)
4.70M(0.73%)
7.46M(1.49%)
11.88M(2.71%)
13.59M(3.89%)
15.98M(4.96%)
15.54M(5.28%)
China
3.18M(0.44%)
4.34M(0.59%)
4.50M(0.70%)
4.70M(0.94%)
6.02M(1.38%)
3.16M(0.90%)
1.48M(0.46%)
--(--)
United Kingdom
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)